AMENDMENTS TO THE SPECIFICATION

IN THE SPECIFICATION

On page 3, line 15, please replace the original paragraph with the following amended paragraph:

-- Fig. 1 (residues 1-1470 of SEQ ID NO: 2) shows the nucleotide sequence of the nucleic acid fragment inserted into the vector for gene therapy prepared in Example 1, together with the amino acid sequence encoded thereby. --

On page 4, line 4, please replace the original paragraph with the following amended paragraph:

-- Fig. 7 (SEQ ID NO: 4) shows the nucleotide sequence of the nucleic acid fragment inserted into the vector for gene therapy prepared in Example 2, together with the amino acid sequence encoded thereby. --

On page 4, line 14, please replace the original paragraph with the following amended paragraph:

-- Fig. 12 (SEQ ID NO: 5) shows the nucleotide sequence of the nucleic acid fragment inserted into the vector for gene therapy prepared in Example 3, together with the amino acid sequence encoded thereby. --

On page 4, line 19, please replace the original paragraph with the following amended paragraph:

-- Fig. 15 (SEQ ID NO: 6) shows the nucleotide sequence of the nucleic acid fragment inserted into the vector for gene therapy prepared in Comparative Example 3, together with the amino acid sequence encoded thereby. --

On page 5, line 1, please replace the original paragraph with the following amended paragraph:

-- Fig. 19 (SEQ ID NO: 7) shows the nucleotide sequence of the nucleic acid fragment inserted into the vector for gene therapy prepared in Example 4, together with the amino acid sequence encoded thereby. --

On page 5, line 11, please replace the original paragraph with the following amended paragraph:

-- Fig. 24 (SEQ ID NO: 8) shows the nucleotide sequence of the nucleic acid fragment inserted into the vector for gene therapy prepared in Example 5, together with the amino acid sequence encoded thereby. --

On page 8, line 26, please replace the original paragraph with the following amended paragraph:

-- PCR was carried out using as a template the cDNA of cultured rat spleen cells stimulated by lection, and using as primers 5'-gagaattcatttaaatgagagcggccgccgtgcccagaaactgtg-3' (SEQ ID NO: 9) and 5'-tcaaccactgcacaaaatcttgggctttacccggagagtgggagagact-3' (SEQ ID NO: 10). Thereafter, PCR was performed using as the template the 300-fold diluted PCR product obtained above, and using as primers 5'-gagaattcatttaaatgagagcggccgccgtgcccagaaactgtg-3' (SEQ ID NO: 11) and 5'-gagagagagaattctcaggtattcatcaaccactgcacaaaatcttgggc-3' (SEQ ID NO: 12). The amplified product was inserted into a cloning site of the above-described expression vector pCAGGS for mammalian cells. By this, pCAGGS-IgG-glu19-29 (pCAGGS in which a nucleic acid fragment having a region coding for the Fc region of immunoglobulin G1 (IgG1) and a region coding for the glucagon-originated label peptide, ligated to the downstream of the Fc-coding region, was inserted at the EcoRI site of pCAGGS), having restriction sites of SwaI and NotI, was obtained. --

On page 9, line 12, please replace the original paragraph with the following amended paragraph:

-- Thereafter, PCR was performed using as a template the cDNA of heart of rat suffering from myocarditis, and using as primers 5'-gagaattcatttaaatgattctgctggtggtcctgatg-3' (SEQ ID NO: 13) and 5'-gcagcatcgcggccgcttcttctctgtcatcatggagaaa-3' (SEQ ID NO: 14). The obtained PCR product was inserted into the pCAGGS-IgG-glu19-29 prepared above using SwaI and NotI. --

On page 11, line 13, please replace the original paragraph with the following amended paragraph:

-- PCR was carried out using as a template the cDNA of cultured rat spleen cells stimulated by lectin, and using as primers 5'-gagaattcatttaaatggcttgtcttggactccagagg-3' (SEQ ID NO: 15) and 5'-gcagcatcgcggccgcgtctgaatctgggcatggttctgg -3' (SEQ ID NO: 16). The obtained PCR product was incorporated into pCAGGS-IgG-glu19-29 prepared by the method described in Example 1, using SwaI and NotI. --

On page 12, line 18, please replace the original paragraph with the following amended paragraph:

-- PCR was carried out using as a template the cDNA of cultured rat spleen cells stimulated by lectin, and using as primers 5'-gagaattcatttaaatggcactctgggtgactgcagtc-3' (SEQ ID NO: 17) and 5'-gcagcatcgcggccgcgtggccatagcggaaaagttgctt-3' (SEQ ID NO: 18). The obtained PCR product was incorporated into pCAGGS-IgG-glu19-29 prepared by the method described in Example 1, using SwaI and NotI. --

On page 13, line 25, please replace the original paragraph with the following amended paragraph:

-- PCR was carried out using as a template the cDNA of cultured mouse spleen cells stimulated by lectin, and using as primers 5'-gagaattcatttaaatggaaatctgctggggaccctac-3' (SEQ ID NO: 19) and 5'-gcagcatcgcggccgcttggtcttcctggaagtagaactt-3' (SEQ ID NO: 20). The obtained

PCR product was incorporated into pCAGGS-IgG-glu19-29 prepared by the method described in Example 1, using SwaI and NotI. --

On page 15, line 2, please replace the original paragraph with the following amended paragraph:

-- To prepare pCAGGS-glu19-29 having SwaI and NotI restriction sites, PCR was performed using as primers 5'-gagaattcatttaaatgagagcggccgccccgggtaaagcccaagattttgtgcagtggttg-3' (SEQ ID NO: 21) and 5'-gagagagagaattctcaggtattcatcaaccactgcacaaaatcttgggc-3' (SEQ ID NO: 22) alone, and the PCR product was inserted into the cloning site of pCAGGS using EcoRI. --

On page 15, line 7, please replace the original paragraph with the following amended paragraph:

-- Thereafter, PCR was performed using the cDNA of Cos7 cells as a template and using as primers 5'-gagaattcatttaaatgacttccaagctggccgtggct-3'(SEQ ID NO: 23) and 5'-gcagcatcgcggccgctgaattctcagccctcttcaaaaa-3' (SEQ ID NO: 24). The PCR product was incorporated into the pCAGGS-glu19-29 prepared above using SwaI and NotI. --